Creative Biolabs is one of the well-recognized expert professionals in the field of complement therapeutics and related services. Our technical experts are looking forward to offering high-quality and custom complement inhibitor validation services for our clients.
The complement system is a cascade reaction playing a pivotal function in recognition and eliminating of invading pathogens, which serves as a regulator of multiple human diseases. About 40 components (proteins and enzymes) form the complement cascade, all of which are indispensable and tightly coordinate with each other to play a normal complement activity. Some of these components positively regulate the complement system so that the complement cascade can be activated to function properly, whereas, others act as inhibitors to regulate the complement system in a negative way to prevent its spontaneous or over-activation.
Until now, a diversity of complement inhibitors has been described, including natural proteins in the complement system and those developed by biotechnology. Complement factor I (CFI), complement factor H (CFH), C4 binding protein (C4BP), decay-accelerating factor (DAF), CD35 (CR1), membrane cofactor protein (MCP), etc., are natural inhibitors regulating complement pathways in different ways. Several complement inhibitors have been approved by Food and Drug Administration (FDA) for the treatment of related diseases, including anti-C5 monoclonal antibody, and C1 esterase inhibitor.
Fig. 1 Complement system and its targeted modulation.1,3
As the revealing of the relationship between the complement system and diseases, increasing complement inhibitors are currently developed and evaluated in clinical trials for the related disease therapy. Therefore, complement inhibition test or complement inhibitor validation is necessary to measure the effect of complement inhibitors.
As an experienced expert in complement therapeutics, Creative Biolabs provides comprehensive custom validation services for the efficient identification of potential complement inhibitors. Based on the principle of combining the individual component activity test with the whole complement cascade activity assessment, our scientists verify or screen complement inhibitors mainly through the following approaches:
With over a decade of experience and the state-of-the-art drug development platforms, Creative Biolabs provides highly custom solutions for complement inhibitors validation to effectively support your anti-complement therapeutics development.
If you are interested, please directly contact us for more information.
Cat | Product Name | PRODUCT TYPE | Target |
---|---|---|---|
CTI-018 | Complement C1 Peptide Inhibitor-PIC1 | Inhibitors | C1q |
CTI-010 | Compstatin | Inhibitors | C3 convertase |
CTI-007 | C3a 70-77 | Inhibitors | C3a |
CTI-001 | SB290157 (Trifluoroacetate) | Inhibitors | C3aR |
CTI-006 | Complement C5-IN-1 | Inhibitors | C5 |
CTI-002 | PMX-53 | Inhibitors | C5a |
CTI-003 | PMX 205 | Inhibitors | C5aR |
CTI-005 | W-54011 | Inhibitors | C5aR |
CTI-012 | ADH-503 | Inhibitors | CD11b |
CTI-013 | Leukadherin-1 | Inhibitors | CD11b |
CTI-009 | FD-IN-1 | Inhibitors | Factor D |
Cat | Product Name | Species | Application |
---|---|---|---|
CTS-001 | Guinea Pig Complement Serum | Guinea pig | Complement activity and function assays |
CTS-003 | Rat Complement Serum | Rat | Complement activity and function assays |
CTS-006 | Human Complement Serum (Pooled) | Human | Complement activity and function assays |
CTS-010 | Mouse Balb C Complement Serum | Mouse | Complement activity and function assays |
CTS-011 | Mouse C57BL6 Complement Serum | Mouse | Complement activity and function assays |
CTS-013 | Monkey Cynomolgus Complement Serum | Monkey | Complement activity and function assays |
CTS-018 | Rabbit Complement Serum | Rabbit | Complement activity and function assays |
CTS-019 | Monkey Rhesus Complement Serum | Monkey Rhesus | Complement activity and function assays |
CTS-020 | Sheep Complement Serum | Sheep | Complement activity and function assays |
CTS-036 | C1q removed Normal Human Serum | Human | Complement activity and function assays |
CTS-037 | C1r removed Normal Human Serum | Human | Complement activity and function assays |
CTS-038 | C1s removed Normal Human Serum | Human | Complement activity and function assays |
CTS-039 | C2 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-040 | C3 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-041 | C4 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-042 | C4 removed Guinea Pig Serum | Guinea Pig | Complement activity and function assays |
CTS-043 | C5 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-044 | C6 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-045 | C7 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-046 | C8 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-047 | C9 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-048 | FB removed Normal Human Serum | Human | Complement activity and function assays |
CTS-049 | FD removed Normal Human Serum | Human | Complement activity and function assays |
CTS-050 | FH removed Normal Human Serum | Human | Complement activity and function assays |
CTS-051 | FI removed Normal Human Serum | Human | Complement activity and function assays |
CTS-052 | FP removed Normal Human Serum | Human | Complement activity and function assays |
CTS-053 | C3&C4 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-054 | C3&C5 removed Normal Human Serum | Human | Complement activity and function assays |
CTS-055 | C3&FB removed Normal Human Serum | Human | Complement activity and function assays |
CTS-056 | C1q&FD removed Normal Human Serum | Human | Complement activity and function assays |
Fig.2 Western-blot assessment of C1INH protein expression and secretion from SERPING1 gene variants linked to HAE.2,3
Hereditary angioedema (HAE) is marked by recurrent and potentially severe edema episodes and exhibits genetic and clinical variability. It is primarily linked to SERPING1 gene mutations that result in insufficient plasma levels of C1 inhibitor (C1INH). To investigate distinct C1INH proteins from these SERPING1 mutations without normal C1INH interference, expression plasmids for each variant were transfected into HeLa cells. Subsequent western blot analysis revealed both intracellular and secreted C1INH. Findings confirmed that post-transfection, HAE-related SERPING1 variants produce C1INH, which is secreted, albeit less efficiently than the normal protein, aligning with previous studies.
References
A: Complement inhibitor validation typically involves several steps, including: (a) In vitro Testing: Assessing the inhibitor's effect on complement activation in controlled cell-based assays or plasma samples. (b) In vivo Studies: Evaluating the inhibitor's impact in animal models, measuring complement inhibition and potential therapeutic effects. (c) Pharmacokinetics (PK) and Pharmacodynamics (PD): Determining how the inhibitor is absorbed, distributed, metabolized, and excreted, as well as its impact on complement activity. (d)Toxicity and Safety Assessment: Investigating potential adverse effects, such as immunogenicity or interference with other physiological processes. (e) Clinical Trials: Conducting controlled human trials to validate safety, efficacy, and dosing regimens.
A: Yes, complement inhibitor validation can be tailored to specific diseases. The choice of assays, models, and endpoints may vary based on the disease's underlying mechanisms and manifestations. Personalized validation approaches may enhance the inhibitor's effectiveness and safety for a particular condition.
A: Technologies, such as ELISA, hemolytic assay, and specific functional experiments. These assay methods allow researchers to study complement dynamics at a finer resolution, enabling more accurate assessments of the inhibitor's effects.
A: We typically require purified complement inhibitors for validation including small molecules, peptides, antibodies, and other therapeutic agents. However, the sample type may vary depending on your specific research objectives and the design of the experiment. In some cases, we might need plasma or serum samples from animal or human sources.
A: The duration of the validation process can vary depending on factors such as the complexity of the inhibitor, the scope of the experiments, and the availability of resources, but a typical timeline for our complement inhibitor validation service is 4-6 weeks. Our team works efficiently to minimize turnaround time while ensuring thorough validation.
A: The final report will outline the objectives of the study, the methodologies we used, and the results of the validation process. This would include a robust data analysis, interpretation of results in context of the study objectives, along with suggestions on any subsequent steps or studies that might be required. Additionally, our team provides ongoing support and consultation to address any questions or concerns related to the validation process or results.